Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab
Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical...
Saved in:
| Published in: | Clinical gastroenterology and hepatology Vol. 15; no. 10; p. 1580 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.10.2017
|
| Subjects: | |
| ISSN: | 1542-7714, 1542-7714 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission in which the drug is titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab.
We performed a multicenter, retrospective study of 264 consecutive patients with IBD (167 with Crohn's disease) receiving infliximab maintenance therapy. The subjects received proactive (n = 130) or reactive (n = 134) drug monitoring, based on measurements of first infliximab concentration and antibodies to infliximab, from September 2006 to January 2015; they were followed through December 2015 (median time of 2.4 years). We analyzed time to treatment failure, first IBD-related surgery or hospitalization, serious infusion reaction, and detection of antibodies to infliximab. Treatment failure was defined as drug discontinuation for loss of response or serious adverse event, or need for surgery.
Multiple Cox regression analysis independently associated proactive drug monitoring, compared with reactive monitoring, with reduced risk for treatment failure (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.09-0.27; P < .001), IBD-related surgery (HR, 0.30; 95% CI, 0.11-0.80; P = .017), IBD-related hospitalization (HR, 0.16; 95% CI, 0.07-0.33; P < .001), antibodies to infliximab (HR, 0.25; 95% CI, 0.07-0.84; P = .025), and serious infusion reaction (HR, 0.17; 95% CI, 0.04-0.78; P = .023).
In a retrospective analysis of patients with IBD receiving proactive vs reactive monitoring of serum concentration of infliximab, proactive monitoring was associated with better clinical outcomes, including greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions. |
|---|---|
| AbstractList | Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission in which the drug is titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab.
We performed a multicenter, retrospective study of 264 consecutive patients with IBD (167 with Crohn's disease) receiving infliximab maintenance therapy. The subjects received proactive (n = 130) or reactive (n = 134) drug monitoring, based on measurements of first infliximab concentration and antibodies to infliximab, from September 2006 to January 2015; they were followed through December 2015 (median time of 2.4 years). We analyzed time to treatment failure, first IBD-related surgery or hospitalization, serious infusion reaction, and detection of antibodies to infliximab. Treatment failure was defined as drug discontinuation for loss of response or serious adverse event, or need for surgery.
Multiple Cox regression analysis independently associated proactive drug monitoring, compared with reactive monitoring, with reduced risk for treatment failure (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.09-0.27; P < .001), IBD-related surgery (HR, 0.30; 95% CI, 0.11-0.80; P = .017), IBD-related hospitalization (HR, 0.16; 95% CI, 0.07-0.33; P < .001), antibodies to infliximab (HR, 0.25; 95% CI, 0.07-0.84; P = .025), and serious infusion reaction (HR, 0.17; 95% CI, 0.04-0.78; P = .023).
In a retrospective analysis of patients with IBD receiving proactive vs reactive monitoring of serum concentration of infliximab, proactive monitoring was associated with better clinical outcomes, including greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions. Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission in which the drug is titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab.BACKGROUND & AIMSMonitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or in patients in clinical remission in which the drug is titrated to a target concentration (proactive drug monitoring). We compared long-term outcomes of patients with IBD undergoing proactive vs reactive monitoring of serum concentrations of infliximab.We performed a multicenter, retrospective study of 264 consecutive patients with IBD (167 with Crohn's disease) receiving infliximab maintenance therapy. The subjects received proactive (n = 130) or reactive (n = 134) drug monitoring, based on measurements of first infliximab concentration and antibodies to infliximab, from September 2006 to January 2015; they were followed through December 2015 (median time of 2.4 years). We analyzed time to treatment failure, first IBD-related surgery or hospitalization, serious infusion reaction, and detection of antibodies to infliximab. Treatment failure was defined as drug discontinuation for loss of response or serious adverse event, or need for surgery.METHODSWe performed a multicenter, retrospective study of 264 consecutive patients with IBD (167 with Crohn's disease) receiving infliximab maintenance therapy. The subjects received proactive (n = 130) or reactive (n = 134) drug monitoring, based on measurements of first infliximab concentration and antibodies to infliximab, from September 2006 to January 2015; they were followed through December 2015 (median time of 2.4 years). We analyzed time to treatment failure, first IBD-related surgery or hospitalization, serious infusion reaction, and detection of antibodies to infliximab. Treatment failure was defined as drug discontinuation for loss of response or serious adverse event, or need for surgery.Multiple Cox regression analysis independently associated proactive drug monitoring, compared with reactive monitoring, with reduced risk for treatment failure (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.09-0.27; P < .001), IBD-related surgery (HR, 0.30; 95% CI, 0.11-0.80; P = .017), IBD-related hospitalization (HR, 0.16; 95% CI, 0.07-0.33; P < .001), antibodies to infliximab (HR, 0.25; 95% CI, 0.07-0.84; P = .025), and serious infusion reaction (HR, 0.17; 95% CI, 0.04-0.78; P = .023).RESULTSMultiple Cox regression analysis independently associated proactive drug monitoring, compared with reactive monitoring, with reduced risk for treatment failure (hazard ratio [HR], 0.16; 95% confidence interval [CI], 0.09-0.27; P < .001), IBD-related surgery (HR, 0.30; 95% CI, 0.11-0.80; P = .017), IBD-related hospitalization (HR, 0.16; 95% CI, 0.07-0.33; P < .001), antibodies to infliximab (HR, 0.25; 95% CI, 0.07-0.84; P = .025), and serious infusion reaction (HR, 0.17; 95% CI, 0.04-0.78; P = .023).In a retrospective analysis of patients with IBD receiving proactive vs reactive monitoring of serum concentration of infliximab, proactive monitoring was associated with better clinical outcomes, including greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions.CONCLUSIONSIn a retrospective analysis of patients with IBD receiving proactive vs reactive monitoring of serum concentration of infliximab, proactive monitoring was associated with better clinical outcomes, including greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions. |
| Author | Ni, Josephine Vajravelu, Ravy K Vaughn, Byron P Osterman, Mark T Papamichael, Konstantinos Chachu, Karen A Cheifetz, Adam S |
| Author_xml | – sequence: 1 givenname: Konstantinos surname: Papamichael fullname: Papamichael, Konstantinos organization: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts – sequence: 2 givenname: Karen A surname: Chachu fullname: Chachu, Karen A organization: Department of Medicine, Division of Gastroenterology, Duke University School of Medicine, Durham, North Carolina – sequence: 3 givenname: Ravy K surname: Vajravelu fullname: Vajravelu, Ravy K organization: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 4 givenname: Byron P surname: Vaughn fullname: Vaughn, Byron P organization: Department of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota – sequence: 5 givenname: Josephine surname: Ni fullname: Ni, Josephine organization: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 6 givenname: Mark T surname: Osterman fullname: Osterman, Mark T organization: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 7 givenname: Adam S surname: Cheifetz fullname: Cheifetz, Adam S email: acheifet@bidmc.harvard.edu organization: Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: acheifet@bidmc.harvard.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28365486$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkN1OGzEQhS0UxG8fgBvkS242tb279u4lhNJGSgUKrXoZOd5xcLS2g-1N4Xl4UUyaSkgjzWh05nyjc4pGzjtA6IKSMSWUf12P1eppzAgVY1LmogfohNYVK4Sg1ejTfIxOY1wTwtqqFUfomDUlr6uGn6C3qd0Ev4UOz7xbFQmCxfdDUt5CxF7jB5kMuBTxH5Oe8NTpXlorkw-v-Mb_hR7fmggyAp6DArM1boUfgpcqmS3gibcbGbL37ngO-_VP70x2-NBmwiOEwWapU5kTMs67HfmDZV6MlctzdKhlH-HLvp-h33fffk1-FLP779PJ9axQdc1TAbTWJW8rzdolAdCs65q2I5pysiQdUZzpsgZZSSFEJxmXSlS17LSUNAfDODtDV_98cyLPA8S0sCYq6HvpwA9xQZumbCpSiiZLL_fSYWmhW2xCfjS8Lv4Hy94BdOiA5Q |
| CitedBy_id | crossref_primary_10_3748_wjg_v25_i41_6172 crossref_primary_10_1016_j_ajg_2021_01_001 crossref_primary_10_1016_j_medcle_2019_07_012 crossref_primary_10_1136_archdischild_2018_315100 crossref_primary_10_1136_flgastro_2019_101372 crossref_primary_10_1177_17562848241280885 crossref_primary_10_3748_wjg_v23_i34_6197 crossref_primary_10_1016_j_cgh_2019_03_037 crossref_primary_10_1093_ibd_izae231 crossref_primary_10_1016_j_cgh_2017_11_033 crossref_primary_10_1097_MCG_0000000000001144 crossref_primary_10_1016_j_pcl_2017_08_008 crossref_primary_10_1111_bcp_14229 crossref_primary_10_3389_fmed_2022_864888 crossref_primary_10_3390_pharmaceutics15071834 crossref_primary_10_1097_FTD_0000000000001044 crossref_primary_10_1093_ecco_jcc_jjy111 crossref_primary_10_1093_ibd_izx023 crossref_primary_10_1093_ecco_jcc_jjz162 crossref_primary_10_1146_annurev_med_052919_120048 crossref_primary_10_1002_ddr_22220 crossref_primary_10_1080_14740338_2018_1413090 crossref_primary_10_1016_j_gastrohep_2020_07_001 crossref_primary_10_3748_wjg_v27_i37_6231 crossref_primary_10_1007_s11938_020_00302_1 crossref_primary_10_3748_wjg_v30_i12_1751 crossref_primary_10_1007_s11938_019_00222_9 crossref_primary_10_1097_MPG_0000000000003389 crossref_primary_10_1007_s10620_018_5144_y crossref_primary_10_1007_s11894_023_00895_4 crossref_primary_10_1093_ecco_jcc_jjaa029 crossref_primary_10_3390_jcm10225311 crossref_primary_10_1177_2050640619854671 crossref_primary_10_14309_ajg_0000000000000783 crossref_primary_10_1136_flgastro_2018_101024 crossref_primary_10_1111_apt_14368 crossref_primary_10_1016_j_cgh_2017_11_046 crossref_primary_10_1016_j_cgh_2025_04_025 crossref_primary_10_1007_s12664_020_01047_6 crossref_primary_10_3390_jcm9092896 crossref_primary_10_1093_ibd_izy069 crossref_primary_10_1007_s10620_022_07783_3 crossref_primary_10_1007_s11894_018_0623_z crossref_primary_10_1093_ibd_izy227 crossref_primary_10_1016_S2468_1253_21_00223_5 crossref_primary_10_1080_00365521_2020_1856405 crossref_primary_10_3904_kjim_2017_400 crossref_primary_10_1001_jama_2021_21316 crossref_primary_10_1038_s41575_020_0352_2 crossref_primary_10_1093_ecco_jcc_jjab127 crossref_primary_10_3390_jcm12216796 crossref_primary_10_14309_ajg_0000000000001500 crossref_primary_10_3390_jcm14176119 crossref_primary_10_1007_s40259_021_00507_5 crossref_primary_10_1007_s10620_018_5202_5 crossref_primary_10_3390_life11010065 crossref_primary_10_1093_ibd_izy132 crossref_primary_10_1093_crocol_otz056 crossref_primary_10_1016_j_cgh_2018_09_033 crossref_primary_10_1080_17512433_2024_2403641 crossref_primary_10_1053_j_gastro_2018_02_012 crossref_primary_10_1080_00365521_2018_1481519 crossref_primary_10_3390_jcm9092840 crossref_primary_10_1016_j_cgh_2019_09_041 crossref_primary_10_1177_2040622319838443 crossref_primary_10_1007_s40746_019_00181_4 crossref_primary_10_1093_crocol_otaa050 crossref_primary_10_1080_1744666X_2019_1630273 crossref_primary_10_3389_fped_2021_661536 crossref_primary_10_1007_s10620_020_06645_0 crossref_primary_10_1177_0004563218782286 crossref_primary_10_1053_j_gastro_2018_01_001 crossref_primary_10_3390_pharmaceutics16121577 crossref_primary_10_1016_j_gtc_2020_08_002 crossref_primary_10_3390_life13030680 crossref_primary_10_1097_MOG_0000000000000637 crossref_primary_10_1093_ecco_jcc_jjy109 crossref_primary_10_1093_ibd_izad277 crossref_primary_10_4103_sjg_sjg_3_22 crossref_primary_10_6061_clinics_2019_e824 crossref_primary_10_1016_j_gastrohep_2023_01_009 crossref_primary_10_3390_pharmaceutics17040428 crossref_primary_10_1097_FTD_0000000000001176 crossref_primary_10_36290_vnl_2020_156 crossref_primary_10_3390_molecules26061787 crossref_primary_10_1093_crocol_otz049 crossref_primary_10_1097_BOR_0000000000000713 crossref_primary_10_1007_s11894_018_0648_3 crossref_primary_10_1177_17562848211037849 crossref_primary_10_1080_17425255_2021_2027367 crossref_primary_10_1097_MEG_0000000000002431 crossref_primary_10_1097_MPG_0000000000003794 crossref_primary_10_1007_s10620_024_08802_1 crossref_primary_10_1002_jpn3_12471 crossref_primary_10_1093_ibd_izae239 crossref_primary_10_1093_ibd_izab285 crossref_primary_10_1093_ecco_jcc_jjy039 crossref_primary_10_1093_ibd_izz085 crossref_primary_10_1109_TCBB_2020_3039326 crossref_primary_10_1016_j_cgh_2017_12_030 crossref_primary_10_3233_HAB_210449 crossref_primary_10_1007_s00384_021_03855_4 crossref_primary_10_1111_apt_14458 crossref_primary_10_1080_00365521_2023_2283387 crossref_primary_10_1007_s10620_019_05796_z crossref_primary_10_1016_j_sempedsurg_2024_151398 crossref_primary_10_1055_a_1713_3941 crossref_primary_10_1097_MEG_0000000000002261 crossref_primary_10_1080_00365521_2019_1582693 crossref_primary_10_1080_09546634_2020_1832649 crossref_primary_10_1111_apt_16479 crossref_primary_10_1016_j_carrev_2024_02_018 crossref_primary_10_1111_1751_2980_13261 crossref_primary_10_1016_j_coph_2020_07_012 crossref_primary_10_1097_MPG_0000000000003587 crossref_primary_10_1093_ibd_izaa102 crossref_primary_10_1097_FTD_0000000000000669 crossref_primary_10_1016_j_gastrohep_2024_01_007 crossref_primary_10_1097_MOG_0000000000000536 crossref_primary_10_1097_pq9_0000000000000400 crossref_primary_10_1016_j_clim_2018_03_004 crossref_primary_10_1007_s10620_018_4917_7 crossref_primary_10_1016_j_gtc_2021_12_007 crossref_primary_10_1093_ecco_jcc_jjz018 crossref_primary_10_1097_MOG_0000000000000653 crossref_primary_10_3390_pharmaceutics14051009 crossref_primary_10_1093_ibd_izae140 crossref_primary_10_1093_ibd_izz113 crossref_primary_10_1111_bcp_14654 crossref_primary_10_1053_j_gastro_2019_06_003 crossref_primary_10_1111_bcp_14410 crossref_primary_10_1093_ibd_izz114 crossref_primary_10_1053_j_gastro_2019_08_001 crossref_primary_10_1177_1756284818759930 crossref_primary_10_4240_wjgs_v16_i2_571 crossref_primary_10_1002_pdi3_96 crossref_primary_10_1007_s10620_017_4808_3 crossref_primary_10_1007_s10620_025_09032_9 crossref_primary_10_1111_apt_17313 crossref_primary_10_3390_antib13010016 crossref_primary_10_1097_MPG_0000000000002486 crossref_primary_10_1016_j_gtc_2023_05_002 crossref_primary_10_1208_s12248_025_01050_9 crossref_primary_10_1007_s11894_018_0622_0 crossref_primary_10_1007_s10620_021_07173_1 crossref_primary_10_1093_crocol_otaf028 crossref_primary_10_1016_j_gtc_2023_05_007 crossref_primary_10_1080_00365521_2022_2108684 crossref_primary_10_1097_MCG_0000000000001637 crossref_primary_10_1097_RHU_0000000000001818 crossref_primary_10_1093_ecco_jcc_jjaa161 crossref_primary_10_1002_jpn3_12307 crossref_primary_10_1111_apt_16135 crossref_primary_10_3390_pharmaceutics13081191 crossref_primary_10_14309_ajg_0000000000001396 crossref_primary_10_1208_s12248_018_0257_y crossref_primary_10_1080_10408398_2017_1406333 crossref_primary_10_1002_jac5_1347 crossref_primary_10_1136_bmjgast_2023_001246 crossref_primary_10_1093_ibd_izz131 crossref_primary_10_1159_000515432 crossref_primary_10_1016_j_medcli_2019_07_025 crossref_primary_10_1080_17474124_2018_1494573 crossref_primary_10_1093_jcag_gwaa003 crossref_primary_10_33590_emj_10314245 crossref_primary_10_1080_17425255_2017_1377180 crossref_primary_10_1016_j_cgh_2018_05_010 crossref_primary_10_1093_ibd_izz257 crossref_primary_10_3748_wjg_v28_i21_2282 crossref_primary_10_1093_ibd_izy203 crossref_primary_10_1097_FTD_0000000000001095 crossref_primary_10_1111_bcp_13939 crossref_primary_10_1055_a_2309_6123 crossref_primary_10_1097_MPG_0000000000002304 crossref_primary_10_1093_ecco_jcc_jjaa050 crossref_primary_10_3390_jcm9103142 crossref_primary_10_1097_MPG_0000000000002704 crossref_primary_10_1136_bmjopen_2021_057656 crossref_primary_10_1097_MEG_0000000000002111 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.cgh.2017.03.031 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1542-7714 |
| ExternalDocumentID | 28365486 |
| Genre | Multicenter Study Journal Article Comparative Study |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: T32 DK007066 – fundername: NCATS NIH HHS grantid: UL1 TR000114 – fundername: NIDDK NIH HHS grantid: L30 DK099831 – fundername: NIDDK NIH HHS grantid: T32 DK007760 |
| GroupedDBID | --- --K .1- .FO 0R~ 1B1 1CY 1P~ 29B 4.4 457 53G 5GY 5VS AAEDT AAEDW AALRI AAQFI AAQQT AAXUO ABJNI ABLJU ABMAC ACGFS ADBBV ADPAM AENEX AEVXI AFCTW AFJKZ AFRHN AFTJW AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C45 C5W CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FDB FRP HZ~ IHE KOM M41 MO0 N9A NPM NQ- O9- OBH OC. ON0 OVD P2P RIG ROL RPZ SEL SES TEORI UV1 XH2 Z5R 7X8 AAFWJ EFJIC EFKBS |
| ID | FETCH-LOGICAL-c556t-e15f3694f29b0eef2dd89d0f160b0d0c62f35ea4a777da26ac745adfaa1029262 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 181 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000410988700027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1542-7714 |
| IngestDate | Thu Oct 02 19:03:21 EDT 2025 Thu Jan 02 23:03:27 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | Monitoring Therapy CD Immunogenicity Ulcerative Colitis |
| Language | English |
| License | Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c556t-e15f3694f29b0eef2dd89d0f160b0d0c62f35ea4a777da26ac745adfaa1029262 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/5605429 |
| PMID | 28365486 |
| PQID | 1883840378 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1883840378 pubmed_primary_28365486 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-10-01 |
| PublicationDateYYYYMMDD | 2017-10-01 |
| PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical gastroenterology and hepatology |
| PublicationTitleAlternate | Clin Gastroenterol Hepatol |
| PublicationYear | 2017 |
| References | 29555231 - Clin Gastroenterol Hepatol. 2018 Apr;16(4):598-599 29555230 - Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598 |
| References_xml | – reference: 29555230 - Clin Gastroenterol Hepatol. 2018 Apr;16(4):597-598 – reference: 29555231 - Clin Gastroenterol Hepatol. 2018 Apr;16(4):598-599 |
| SSID | ssj0029497 |
| Score | 2.6102571 |
| Snippet | Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1580 |
| SubjectTerms | Adolescent Adult Drug Monitoring - methods Female Gastrointestinal Agents - administration & dosage Gastrointestinal Agents - blood Humans Inflammatory Bowel Diseases - drug therapy Infliximab - administration & dosage Infliximab - blood Male Retrospective Studies Serum - chemistry Treatment Outcome Young Adult |
| Title | Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28365486 https://www.proquest.com/docview/1883840378 |
| Volume | 15 |
| WOSCitedRecordID | wos000410988700027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELXYhLiw74uMxNUiixPHJ8RWgURLhUD0VjleIBJNgLTA__CjeGIXLhyQuORgxZoonrw8zxvPIHRgBM-FSUOS00wTKHFOhIkEEXBqMQNCzUXTbIJ1Olmvx7s-4Fb7tMoxJjZArSoJMfLDMMtiuxmJWXb0_EKgaxSoq76FxiSaji2VAa9mvW8VIeLUNVdJKLDIkI5VzSa_Sz6AFhGypsap7zH3K8Ns_jSthf8-4yKa9xwTHzunWEITulxGs22voq-gTxdJ0ApfVeUDAXDG16OhtaFrXBncdbVWa3xfDB_xZWms1wwaNR6fVO_6CZ85VQdbzqkLiEjgLhzMAuTEpz6p3U2-0X7YYQcEEcGCRajRwN5autzQxvdhHGwVH8VA5KvornV-e3pBfLMGIpMkHRIdJiZOOTURzwOtTaRUxlVgwjTIAxXINDJxogUVjDElolRIRhOhjBCW4kDRwjU0VVal3kA4ELFRUiaW3Fi2psI8kQE1VDFmuOZ5von2x6-_bz8GUDhEqatR3f9ZgE207taw_-yqdvQtj0rt9izd-sPsbTQHruGS9nbQtLFQoHfRjHwbFvXrXuNl9trptr8A8Mjgew |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improved+Long-term+Outcomes+of+Patients+With+Inflammatory+Bowel+Disease+Receiving+Proactive+Compared+With+Reactive+Monitoring+of+Serum+Concentrations+of+Infliximab&rft.jtitle=Clinical+gastroenterology+and+hepatology&rft.au=Papamichael%2C+Konstantinos&rft.au=Chachu%2C+Karen+A&rft.au=Vajravelu%2C+Ravy+K&rft.au=Vaughn%2C+Byron+P&rft.date=2017-10-01&rft.issn=1542-7714&rft.eissn=1542-7714&rft.volume=15&rft.issue=10&rft.spage=1580&rft_id=info:doi/10.1016%2Fj.cgh.2017.03.031&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1542-7714&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1542-7714&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1542-7714&client=summon |